AlphAIAlphAI — Financial news for AI agents
investing.comNOV 32 min read$SNDX

Mizuho reiterates Outperform on Syndax stock, $43 target

Mizuho reiterated an Outperform rating and $43 target on Syndax Pharmaceuticals (SNDX) after its Q3 2026 earnings. Revenue was $60.7M for Revuforj, slightly below estimates but up 11% QoQ. The stock is near its 52-week low, down 38% YTD. Analysts maintain a Strong Buy consensus. Syndax reported total revenue of $83.3M, beating estimates, with an adjusted loss per share of $0.55.

Original reporting
investing.com
Published Nov 3, 2026, 8:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 8:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$SNDX
Bullish
medium confidence
Mentioned
$SNDX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SNDXBullishMed
01

Why it matters

The earnings release provides fresh guidance and a higher price target, offering a catalyst for short‑term traders.

02

Market read

First‑time earnings disclosure with upgraded target creates a modest trading opportunity in the biotech space.

03

What to watch

Potential headwinds from transplant‑related sales slowdown and weak gross margins may limit upside.

Relevance 7/10Novelty 8/10Timing: post‑market today

Background

Syndax is a small‑cap biotech developing Revuforj and Niktimvo for NPM1‑mutated leukemia patients.

Company-level read

Ticker impact

$SNDXBullishMedium confidence
Context

Syndax Pharmaceuticals reported its Q3 2026 earnings, posting revenue, loss per share and a new $43 price target.

Expected impact

likely upward pressure as analysts raise target to $43

Evidence & confidence

The earnings release includes higher-than-expected revenue and a substantial price‑target increase, which may attract buying interest.

Market effects

Sector

Positive earnings may lift other biotech stocks focused on hematology/oncology.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

The stock remains far below the new target, but execution risk on upcoming trials could keep it depressed.

Key entities

  • analyst
    Mizuho

    Raised rating to Outperform and set $43 price target.

Read at source← All news

StorySyndax Pharmaceuticals reports Q3 2026 earnings with 82% revenue jump and narrowed loss

Also covered by

3 outlets

Related articles

NOV 3
$SNDXMed

What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call

Syndax Pharmaceuticals (SNDX) reported Q3 earnings, highlighting Revuforj's increasing use before and after stem cell transplants. Niktimvo revenue rose 47% YoY to $67M, with collaboration revenue at $22.6M. The company expects more KMT2A patients to resume treatment post-transplant and anticipates meaningful revenue impact in 2027. Syndax plans to present Revuforj data in Q4 and advance its pipeline, including submissions for SNDX-4321 by late 2026.

finance.yahoo.com3 min
NOV 2
$SNDXHighAI 8/10

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update • Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – Revuforj ® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R

SEC EDGAR 8-K2 min
NOV 2
$SNDXLow

Syndax's new finance chief starts Nov. 9; his predecessor stays through year-end

Syndax Pharmaceuticals (SNDX) appointed Aaron A. Ondrey as CFO, effective Nov. 9, 2026. Keith A. Goldan, the outgoing CFO, will stay until year-end to support the transition. Ondrey has 25 years of biotech finance experience, previously serving as CFO at Beren Therapeutics and Rocket Pharmaceuticals. Goldan led Syndax's financial strategy during key growth periods, including FDA approvals for Revuforj and Niktimvo.

stocktitan.net1 min
NOV 2
$SNDXMed

About 20% more patients started Syndax's leukemia drug in Q3 than Q2; new data are expected in Q4.

Syndax Pharmaceuticals reported Q3 2026 revenue of $60.7M for Revuforj and $67.4M for Niktimvo, with Revuforj showing 90% YoY growth. The company expects new data on Revuforj in Q4 2026 from multiple clinical trials and real-world studies. Syndax plans to initiate the RAVEN trial in Q4 2026 and the MenTain trial in Q1 2027. The company will host a conference call today at 4:30 p.m. ET.

stocktitan.net2 min
OCT 14
$SNDXMedAI 8/10

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

Syndax Pharmaceuticals' stock fell 15.7% after its Phase II study of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet the primary endpoint. The company will discontinue IPF development, but continues cGVHD programs. Axatilimab is already FDA-approved for cGVHD. Year-to-date, SNDX shares have dropped 33.6%.

zacks.com2 min